Drugs Containing Excipient (Inactive Ingredient) POPPY SEED OIL

Branded drugs containing POPPY SEED OIL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Guerbet LLC	LIPIODOL	ethiodized oil	67684-1901	POPPY SEED OIL	1969-12-31

Generic drugs containing POPPY SEED OIL excipient

Company	Ingredient	NDC	Excipient
Guerbet LLC	ethiodized oil	67684-1901	POPPY SEED OIL

Last updated: August 2, 2026

Poppy seed oil is a niche pharmaceutical excipient with limited standalone market visibility. Its commercial value comes from use as a fixed-oil vehicle, solvent, emollient, and formulation component rather than from ownership of a proprietary active ingredient. Demand is likely to remain stable to moderately growing, supported by specialty formulations, nutraceutical overlap, and regional pharmaceutical manufacturing. The main constraints are batch consistency, oxidation control, residual opiate alkaloids, regulatory qualification, and competition from better-established injectable and oral oils.

Poppy Seed Oil Pharmaceutical Excipient Market Dynamics, Financial Trajectory, and Patent Landscape

What is the pharmaceutical role of poppy seed oil?

Poppy seed oil is a fixed vegetable oil obtained from the seeds of Papaver somniferum. It is chemically distinct from opium and does not function as an opioid active pharmaceutical ingredient. Its pharmaceutical value comes from its lipid properties.

Typical functions include:

• Vehicle or solvent for lipophilic drug substances
• Oil phase in soft-gel capsules
• Emollient in topical and dermatological products
• Carrier in depot or sustained-release systems
• Component in lipid-based delivery systems
• Nutraceutical and medical-food ingredient

The oil contains a high proportion of unsaturated fatty acids, particularly linoleic acid. That profile gives it useful spreadability and solvent capacity but also increases sensitivity to oxidation. Pharmaceutical-grade material therefore requires control of peroxide value, acid value, moisture, impurities, microbial quality, and storage conditions.

Poppy seed oil is generally a formulation excipient, not a drug substance. It does not receive an independent FDA New Drug Application, biologics license, or Orange Book listing.

How large is the pharmaceutical poppy seed oil market?

No authoritative public source reports a standalone global market size for pharmaceutical-grade poppy seed oil. Suppliers typically group it with specialty vegetable oils, pharmaceutical excipients, cosmetic oils, or nutraceutical ingredients.

The addressable market is small relative to soybean oil, sesame oil, castor oil, medium-chain triglycerides, mineral oil, and oleic-acid-based excipients. Its economics are therefore determined by specialty-grade premiums rather than volume scale.

Market characteristic	Poppy seed oil position
Primary category	Specialty fixed-oil excipient
Main pharmaceutical use	Vehicle, oil phase, emollient, lipid carrier
Standalone market reporting	Limited or unavailable
Volume profile	Niche
Value driver	Qualification, purity, documentation, and formulation performance
Main competitors	Sesame oil, soybean oil, castor oil, olive oil, MCT oil, ethyl oleate
Key technical risk	Oxidation and compositional variability
Key regulatory risk	Residual opiate alkaloids and supply-chain controls
Patent concentration	Low for the oil itself; higher for finished formulations

Revenue exposure is rarely disclosed by pharmaceutical manufacturers because the oil represents a minor bill-of-materials cost. A formulation company may generate substantial product revenue while reporting no separate financial contribution from the excipient.

What drives the financial trajectory for pharmaceutical poppy seed oil?

The financial trajectory is likely to be stable rather than explosive. Growth depends on new formulation approvals and platform adoption, not on broad substitution into existing medicines.

Demand drivers

Demand can increase when formulators require:

• A nonaqueous carrier for poorly water-soluble compounds
• A vegetable-derived oil for oral or topical products
• A lipid phase with a specific fatty-acid profile
• A natural-origin excipient for consumer-facing products
• A replacement for mineral or synthetic oil
• A specialty vehicle for low-volume products

Poppy seed oil can also benefit from the growth of soft-gel products and lipid-based delivery systems. Those applications often use combinations of oils, surfactants, and co-solvents rather than a single oil.

Financial constraints

The oil faces several commercial limitations:

1. Low switching costs for noncritical applications.
   A customer may substitute sesame, olive, soybean, or MCT oil after reformulation and stability work.

2. Limited differentiation.
   The oil is generally sold as a material rather than as a protected delivery platform.

3. Qualification costs.
   Pharmaceutical customers require supplier audits, analytical specifications, change-control commitments, traceability, and stability data.

4. Oxidative instability.
   Unsaturated oil can require antioxidants, nitrogen blanketing, light protection, and controlled storage.

5. Small customer base.
   The principal buyers are specialty drug manufacturers, contract development and manufacturing organizations, compounding suppliers, and nutraceutical producers.

6. Regulatory scrutiny of poppy-derived materials.
   Even when the product is seed oil rather than opium, customers may require evidence that alkaloid contamination is controlled.

Which pharmaceutical applications use poppy seed oil?

Oral and soft-gel formulations

Poppy seed oil can act as a lipid vehicle for compounds with poor aqueous solubility. Its suitability depends on drug solubility, digestion behavior, oxidative stability, capsule compatibility, and bioavailability performance.

In soft-gel products, formulators compare it with:

• Medium-chain triglycerides
• Long-chain triglycerides
• Olive oil
• Soybean oil
• Corn oil
• Sesame oil
• Caprylic/capric triglycerides

MCT oils often have an advantage in oxidation resistance and standardized composition. Poppy seed oil may remain attractive where a natural long-chain oil or specific sensory profile is required.

Topical and dermatological products

The oil can function as an emollient and spreading agent. These applications compete with refined plant oils, mineral oil, hydrogenated oils, esters, and synthetic emollients.

The technical decision usually turns on:

• Skin feel
• Oxidative stability
• Odor
• Color
• Absorption rate
• Compatibility with preservatives and active ingredients
• Regulatory acceptance in the target market

Injectable and depot formulations

Injectable use has a much higher qualification burden. Sterility, endotoxin control, particulate limits, extractables, degradants, and long-term stability become critical.

Poppy seed oil should not be treated as interchangeable with sesame or castor oil in an injectable product. A change in oil can affect viscosity, release rate, tissue tolerability, syringeability, container compatibility, and impurity formation. Any such substitution generally requires formulation development and regulatory support.

Publicly available information does not establish poppy seed oil as a broadly used default vehicle for FDA-approved injectable products. Established injectable oils have stronger precedent in approved products and compendial practice.

What is the FDA regulatory status of poppy seed oil as an excipient?

The FDA does not generally approve excipients through a standalone approval pathway. An excipient is evaluated as part of a finished drug product, and the sponsor must demonstrate that the formulation is suitable for its intended route, dose, quality, and use.

The principal regulatory mechanisms are:

• Inclusion in an FDA-approved drug product
• Appearance in the FDA Inactive Ingredient Database, where applicable
• Compliance with applicable USP-NF or other recognized standards
• Supplier qualification and manufacturing controls
• Product-specific safety and quality justification

The FDA Inactive Ingredient Database is the main public reference for excipient precedent in approved drug products. It provides route-specific and dosage-form information for inactive ingredients with historical approval experience. Presence in the database does not mean that every concentration, route, or product design is automatically acceptable. Absence does not necessarily prohibit use, but it increases the sponsor’s burden to justify safety and quality.

Poppy seed oil suppliers must also operate within current good manufacturing practice expectations applicable to drug components and finished products. Relevant controls include identity, purity, contamination, storage, packaging, and change management under 21 C.F.R. Parts 210 and 211.

What is the Orange Book status of poppy seed oil?

Poppy seed oil has no independent Orange Book status.

The Orange Book lists approved drug products and patent or exclusivity information associated with those products. An excipient is not listed as an independent Orange Book product. If an approved drug uses poppy seed oil, any Orange Book patent listing would relate to the drug product, formulation, method of use, or delivery system, not to the commodity oil as such.

This distinction affects generic-entry analysis:

• There is no standalone poppy seed oil Paragraph IV pathway.
• There is no excipient-specific Orange Book exclusivity period.
• A generic sponsor may need to address patents covering the finished dosage form or method of treatment.
• The oil supplier is usually not the relevant patent owner in a drug-product dispute.

What patents protect pharmaceutical formulations containing poppy seed oil?

The oil itself is unlikely to have a commercially meaningful composition patent because fixed vegetable oils are established natural materials with known chemical profiles. Patent value generally resides in the finished formulation.

Potential patent categories include:

Formulation patents

These may claim:

• A drug dissolved or dispersed in poppy seed oil
• A defined oil concentration range
• A mixture of poppy seed oil with surfactants or co-solvents
• A lipid formulation that improves bioavailability
• A capsule or emulsion containing the oil
• An antioxidant system that stabilizes the oil phase

Method-of-use patents

A patent may claim administration of a drug using a formulation containing poppy seed oil for:

• Improved absorption
• Sustained release
• Reduced dosing frequency
• Treatment of a particular disease
• Reduction of local irritation
• Delivery of a poorly soluble compound

Manufacturing patents

Manufacturing claims may cover:

• Refining or deodorization
• Removal of residual alkaloids
• Controlled oxidation levels
• Sterilization or filtration
• Encapsulation
• Preparation of an oil-in-water or water-in-oil emulsion

The strongest enforceable rights usually attach to a defined finished formulation or therapeutic use. A broad claim to “a pharmaceutical composition comprising poppy seed oil” may face prior-art and written-description challenges if the oil is already known as a conventional vehicle.

When does poppy seed oil lose exclusivity?

Poppy seed oil does not have a drug-style exclusivity date.

A supplier generally sells the material under:

• Trade secret manufacturing controls
• Quality specifications
• Supply agreements
• Trademark or branding rights
• Potential process patents
• Customer-specific qualification status

Any patent covering a refining process, stabilized composition, drug formulation, or delivery system expires according to the specific patent family. There is no single expiration date for the excipient category.

For a finished drug, loss of exclusivity depends on:

1. Regulatory exclusivity for the drug product
2. Orange Book-listed patents
3. Nonlisted formulation and method-of-use patents
4. Patent-term adjustments or extensions
5. Paragraph IV litigation
6. Settlement agreements
7. Generic development and commercial strategy

Are there Paragraph IV challenges involving poppy seed oil?

No standalone Paragraph IV challenge is expected for poppy seed oil because it is not an independently approved drug product.

Paragraph IV disputes can arise where a finished generic drug contains poppy seed oil and the reference product has Orange Book-listed patents. The dispute would concern the approved drug product, not the excipient’s general availability.

A generic applicant could challenge patents covering:

• The drug formulation
• The oil-to-drug ratio
• A soft-gel or emulsion system
• A controlled-release profile
• A method of treating a specified condition

The use of a commonly available excipient does not itself create freedom to operate if the finished formulation is claimed by an enforceable patent.

Which companies supply pharmaceutical-grade poppy seed oil?

The supplier landscape is fragmented. Poppy seed oil may be sourced from:

• Specialty pharmaceutical-excipient distributors
• Vegetable-oil processors
• Nutraceutical ingredient suppliers
• Cosmetic raw-material companies
• Contract manufacturers
• Regional agricultural processors

Large excipient suppliers tend to prioritize high-volume materials with established pharmacopeial demand. Poppy seed oil is more likely to be supplied through specialty channels than through the largest global excipient portfolios.

Commercial diligence should focus on:

• Botanical source and country of origin
• Seed authentication
• Alkaloid testing
• Refining method
• Fatty-acid profile
• Peroxide and anisidine values
• Residual solvent profile
• Microbial specifications
• Container and closure system
• Retest period
• Change-control obligations
• Backup manufacturing capacity

A second-source strategy is important because agricultural oils can be exposed to crop variability, geopolitical disruption, freight costs, and regional regulatory changes.

How does poppy seed oil compare with competing pharmaceutical oils?

Excipient	Relative strength	Main limitation
Poppy seed oil	Natural-origin positioning and long-chain lipid functionality	Limited pharmaceutical precedent and alkaloid-control concerns
Sesame oil	Established injectable and pharmaceutical precedent	Allergens, oxidation, sensory profile
Soybean oil	Broad availability and extensive formulation history	Oxidation, allergen and source controls
Castor oil	Strong solvent capacity for some lipophilic drugs	High viscosity and tolerability concerns
MCT oil	Oxidative stability and standardized composition	Different absorption and solvent behavior
Olive oil	Consumer familiarity and topical utility	Variable composition and limited use in some dosage forms
Mineral oil	Chemical stability and low cost	Lower natural-origin positioning and route-specific limitations
Ethyl oleate	Useful injectable and depot properties	Synthetic or semisynthetic positioning and formulation-specific tolerability

Poppy seed oil is most competitive where a customer values its natural origin or specific lipid behavior. It is less competitive where regulatory precedent, oxidation resistance, or large-scale supply is the primary purchasing criterion.

What manufacturing and intellectual-property barriers affect the market?

The main barriers are technical and regulatory rather than patent-based.

Manufacturing barriers

Manufacturers must manage:

• Agricultural variability
• Oxidation during extraction and storage
• Residual seed contaminants
• Alkaloid carryover
• Trace metals and pesticides
• Batch-to-batch fatty-acid variation
• Deodorization effects
• Packaging oxygen permeability

Cold-pressed, refined, and pharmaceutical-grade oils can have materially different impurity profiles. A customer cannot assume that food-grade or cosmetic-grade material is suitable for a drug product.

Intellectual-property barriers

IP barriers are more likely to involve:

• A proprietary stabilized oil system
• A drug-specific lipid formulation
• A controlled-release dosage form
• A patented purification process
• A supplier’s analytical method or manufacturing know-how

The commodity oil itself generally has low patent defensibility. Supplier advantage is more likely to come from qualification history, reliable documentation, and consistent quality.

What is the generic-entry and biosimilar risk?

Generic-entry risk is indirect. A supplier of poppy seed oil may lose volume if a branded drug using the oil faces generic erosion, but the excipient can also gain volume if multiple generic manufacturers adopt the same formulation.

Biosimilar risk is usually not relevant because biosimilars are biologic products and generally do not use fixed oils as primary formulation vehicles. Poppy seed oil is more relevant to small-molecule oral, topical, depot, and specialty drug products.

Generic launch scenarios include:

• No impact if the oil is not used in the reference product
• Volume expansion if several generics use the oil
• Volume decline if generic developers substitute a lower-cost oil
• Temporary demand increases during launch inventory build
• Long-term price pressure after multi-source competition develops

What licensing deals and settlements affect poppy seed oil?

There is no widely reported licensing market centered on poppy seed oil as a standalone excipient. Licensing activity is more likely to concern:

• A drug formulation using the oil
• A soft-gel delivery platform
• A sustained-release injectable
• A lipid-based absorption technology
• A contract manufacturing or supply agreement

Similarly, patent settlements would generally be between branded and generic drug companies. The excipient supplier may remain outside the litigation unless its manufacturing process or product specifications are directly accused.

What is the commercial outlook for pharmaceutical poppy seed oil?

The outlook is niche and application-driven.

Period	Likely market condition
Near term	Stable demand, with pricing influenced by raw-material and compliance costs
Medium term	Selective growth in specialty oral, topical, and lipid-based formulations
Longer term	Greater pressure from standardized MCT and synthetic lipid alternatives

Upside depends on successful qualification in approved products and evidence of superior formulation performance. Downside risk comes from substitution, limited regulatory precedent, raw-material variability, and customer reluctance to use a poppy-derived material where a more standardized oil is available.

The strongest commercial strategy is to sell a documented pharmaceutical-grade material with validated impurity controls, not an undifferentiated agricultural oil.

Key Takeaways

• Poppy seed oil is a niche fixed-oil pharmaceutical excipient, not an active drug.
• No reliable standalone public market-size figure is available for pharmaceutical-grade poppy seed oil.
• Its value is concentrated in specialty formulations, soft gels, topical products, and selected lipid-based systems.
• The oil has no independent Orange Book listing, FDA exclusivity period, or Paragraph IV pathway.
• Formulation, method-of-use, and manufacturing patents may protect products containing the oil.
• Residual opiate alkaloids, oxidation, agricultural variability, and route-specific quality requirements are the main barriers.
• MCT oil, sesame oil, soybean oil, castor oil, and ethyl oleate are the principal alternatives.
• Financial performance is likely to track qualification wins and formulation adoption rather than commodity volume growth.
• Biosimilar exposure is minimal; generic exposure is indirect and depends on the finished drug.
• Supplier differentiation will depend on quality systems, analytical documentation, regulatory history, and supply continuity.

FAQs

Is poppy seed oil the same as opium oil?

No. Poppy seed oil is a fixed vegetable oil extracted from seeds. Opium is a latex-derived material containing opioid alkaloids. Regulatory and pharmaceutical functions are different.

Can poppy seed oil be used in injectable medicines?

It may be technically possible in a specific formulation, but injectable use requires extensive route-specific quality, sterility, safety, stability, and regulatory support. Food-grade or cosmetic-grade oil is not sufficient.

Does poppy seed oil contain morphine?

Poppy seeds can carry residual opiate alkaloids from contact with the plant. The risk depends on seed source and processing. Pharmaceutical suppliers should establish validated controls and testing for relevant alkaloids.

Is poppy seed oil listed in the FDA Inactive Ingredient Database?

The FDA Inactive Ingredient Database is the controlling public reference for route- and dosage-form-specific precedent. A general assumption that a vegetable oil is acceptable does not replace verification of the applicable database entry and product-specific justification.

Can a generic drug freely substitute poppy seed oil for sesame oil?

No. Substitution can change solubility, release, absorption, stability, viscosity, tolerability, and impurity profiles. A generic sponsor must evaluate the change under applicable product-development and regulatory requirements.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2023). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Part 211. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211

4. U.S. Food and Drug Administration. (2023). Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs, 21 C.F.R. Part 210. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210

5. European Food Safety Authority. (2011). Scientific opinion on the risks for public health related to the presence of opium alkaloids in poppy seeds. EFSA Journal, 9(11), 2405. https://doi.org/10.2903/j.efsa.2011.2405

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

7. World Health Organization. (2016). WHO good manufacturing practices for pharmaceutical products: Main principles. World Health Organization.